Efficacy and safety of a hydrocortisone aceponate‐containing ear spray solution in dogs with erythemato‐ceruminous otitis externa: A randomised, multicentric, single‐blinded, controlled trial
Veterinary Dermatology · 2024-04 · 35 (2) · 197-206
DOI: 10.1111/vde.13224 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Veterinary Dermatology, online erschienen am 13.12.2023. Verfasst von Delphine Rigaut und 3 weiteren Autor:innen. Beteiligte Einrichtung: Virbac SA, Carros, France. Hauptthemen laut MEDLINE: Dog Diseases, Hydrocortisone, Otitis Externa. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Virbac S.A..
Abstract (Originalsprache)
Background
Erythemato‐ceruminous otitis externa (ECOE) is frequently seen in dogs affected with an allergic skin disease, with recurrent secondary bacteria and yeast overgrowths (detected on cytological examination).
Objectives
The objective of the study was to compare the efficacy and safety of an ear spray containing only hydrocortisone aceponate glucocorticoid diester (HCA) to a control product (CTRL), an approved otic formulation containing prednisolone‐miconazole‐polymyxin combination, in dogs with ECOE. Animals In total, 97 and 104 dogs with ECOE were respectively randomly assigned to the tested ear treatment product group (HCA) or the commercially available ear treatment control product group (CTRL). Materials and Methods Dogs were treated for 7–14 days, as needed. At Day (D)0, D7, D14, D28 and D42, Otitis Index Score‐3, hearing test, pruritus and pain visual analogue scales, and cytological scores were graded. The overall response to treatment also was assessed.
Results
All clinical parameters decreased rapidly and in a similar way without any significant difference at any time between treatment groups. A good‐to‐excellent response to treatment was seen in >90% of dogs of both groups as early as D14. The treatment was considered safe in all dogs. Conclusions and Clinical Relevance A 7‐ to 14‐day ear topical application of HCA alone to dogs with ECOE accompanied with bacterial and/or fungal (yeast) overgrowth was safe and led to no statistical difference in improvement of clinical scores relative to the CTRL combination. Based on these results, it may be necessary to reconsider the routine use of antimicrobial drugs such as antibiotics and antifungals as a first‐line treatment for ECOE that is likely to have been caused by an allergic reaction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Virbac SA, Carros, France.
ORCID-Profile: Pierre Jasmin
Förderung
- Virbac S.A.
Zitieren
APA
Rigaut, D., Briantais, P., Jasmin, P., & Bidaud, A. (2024). Efficacy and safety of a hydrocortisone aceponate‐containing ear spray solution in dogs with erythemato‐ceruminous otitis externa: A randomised, multicentric, single‐blinded, controlled trial. Veterinary Dermatology, 35(2), 197-206. https://doi.org/10.1111/vde.13224
Vancouver
Rigaut D, Briantais P, Jasmin P, Bidaud A. Efficacy and safety of a hydrocortisone aceponate‐containing ear spray solution in dogs with erythemato‐ceruminous otitis externa: A randomised, multicentric, single‐blinded, controlled trial. Veterinary Dermatology. 2024;35(2):197-206. doi:10.1111/vde.13224
BibTeX
@article{Rigaut2024,
author = {Rigaut, Delphine and Briantais, Philippe and Jasmin, Pierre and Bidaud, Alice},
title = {Efficacy and safety of a hydrocortisone aceponate‐containing ear spray solution in dogs with erythemato‐ceruminous otitis externa: A randomised, multicentric, single‐blinded, controlled trial},
journal = {Veterinary Dermatology},
year = {2024},
volume = {35},
number = {2},
pages = {197--206},
doi = {10.1111/vde.13224}
}
EUVIMED